5.32306
PAS Kinase Inhibitor, BioE-1115
Synonym(s):
PAS Kinase Inhibitor, BioE-1115, PASK Inhibitor, 2-(4-Fluorophenyl)-3-(isopropyl(methyl)amino)quinoxaline-6-carboxylic acid, BioE1115, Per-Arnt-Sim Domain Kinase Inhibitor, PAS Domain Kinase Inhibitor
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
| Size/SKU | Availability | Price |
|---|---|---|
10 mg | Check Cart for Availability | $243.00 |
About This Item
Empirical Formula (Hill Notation):
C19H18FN3O2
CAS Number:
Molecular Weight:
339.36
MDL number:
NACRES:
NA.77
UNSPSC Code:
51111800
Assay:
≥97% (HPLC)
Form:
powder
Storage condition:
OK to freeze, protect from light
assay
≥97% (HPLC)
Quality Segment
form
powder
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze, protect from light
color
yellow
solubility
DMSO: 50 mg/mL
storage temp.
2-8°C
General description
A cell-permeable quinoxaline-carboxylic acid compound that acts as a selective PAS kinase/PASK inhibitor (IC50 ~ 4 nM) with little or no potency against a panel of 49 other kinases (IC50 ≥ 10 µM) and effectively inhibits cellular PASK-T307 autophosphorylation (IC50 ~ 1 µM; 16 h drug treatment in PASK-transfected HEK293T cultures with 1% FBS). Similar to siRNA-mediated PASK knockdown, BioE-1115 treatment is shown to effectively prevent sterol regulatory element binding protein SREBP-1c maturation without affecting Akt/mTOR pathway signaling, resulting in impaired cellular SREBP transcription activity in HepG2 cultures (% inhibition/[drug] = 40%/30 µM & & 65%/50 µM by SRE-Luc reporter assay; overnight drug treatment prior to 100 nM insulin stimulation for 6 h). Oral administration is reported to effectively reduce high-frucose diet/HFrD-induced dyslipidemia (% reduction of liver triglyceride/serum triacylglyerol/dose = 48/26/30 mg kg-1 & 63/55/100 mg kg-1; Daily oral dosage administered in the last wk of a 3 wk HFrD period, followed by a 24 h fasting and a 12 refed period prior to tissue collection) and insulin resistance (% reduction of serum glucose/insulin/dose = 23/14/30 mg kg-1 & 28/31/100 mg kg-1) in rats by selectively suppressing SREBP-1 maturation and thereby inhibiting SREBP-1c, but not SRREBP-2, target genes transcription in liver, but not in abdominal fat or gastrocnemius muscle in vivo (% Gpat1/Fasn/Scd1/Acc1/Fae mRNA reduction/plasma [BioE-1115] in µg/mL/dose = 40/34/36/27/34/2.07/10 mg kg-1, 59/56/51/48/54/7.65/30 mg kg-1, 76/5967/62/74/42.2/100 mg kg-1) without affecting liver or body weight.
A cell-permeable, orally available, non-toxic quinoxaline-carboxylic acid based compound that acts as a highly potent, selective, and reversible inhibitor of Per-Arnt-Sim Kinase (PASK; IC50 ~ 4 nM). Exhibits excellent selectivity over 49 other kinases (IC50 >10 µM) and displays about 2,500-fold greater potency for PASK over casein kinase 2α. Blocks PASK autophosphorylation at Thr307 in a dose-dependent manner (IC50 ~ 1 µM) without affecting the insulin-induced phosphorylation of either Akt or S6K. Effectively blocks the maturation of SREBP-1 in hepatic tissue of high fructose fed wild-type Sprague-Dawley rats. Shown to normalize hepatic and serum triglyceride levels, reduce blood glucose levels, and partially reverse insulin resistance in animal models (30 mg/kg. p.o.).
Please note that the molecular weight for this compound is batch-specific due to variable water content.
Please note that the molecular weight for this compound is batch-specific due to variable water content.
BioE-1115, PASKi
Biochem/physiol Actions
Cell permeable: yes
Primary Target
PASK
PASK
Preparation Note
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Other Notes
Wu, X., et al. 2014. Cell Rep.8, 242.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Standard Handling (A)
1 of 1
This Item | |||
|---|---|---|---|
| description - | description - | description - | description The TGF-β RI Kinase Inhibitor, also referenced under CAS 396129-53-6, controls the biological activity of TGF-β RI Kinase. This small molecule/inhibitor is primarily used for Phosphorylation & Dephosphorylation applications. |
| assay ≥97% (HPLC) | assay ≥95% (HPLC) | assay ≥98% (HPLC) | assay ≥97% (HPLC) |
| form powder | form powder | form solid | form solid |
| manufacturer/tradename Calbiochem® | manufacturer/tradename Calbiochem® | manufacturer/tradename Calbiochem® | manufacturer/tradename Calbiochem® |
| Quality Level 100 | Quality Level 100 | Quality Level 100 | Quality Level 200 |
| storage temp. 2-8°C | storage temp. 2-8°C | storage temp. 2-8°C | storage temp. 2-8°C |
| solubility DMSO: 50 mg/mL | solubility DMSO: 100 mg/mL, water: 2.5 mg/mL | solubility DMSO: 50 mg/mL | solubility DMSO: 5 mg/mL |
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.